7 doctors with impressive backgrounds, speaks volumes:

Dr. Ferenc joins a growing all-star medical advisory team that already has the following members:

Dr. Channing Coe joins Canbiola as Medical Advisor and Distributor

Dr. Robert A. Kornfeld Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor

Dr. John P. Salerno Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor

Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor

Dr. Harry Benisatto joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor

Dr. Smita Ohri joins Canbiola as Medical Advisor and Distributor

There it is. Last target estimate I saw was $2,500

Canbiola, Inc. (CANB) Announces New Chief Operations Officer to Oversee Daily Operations and Manufacturing
GlobeNewswire
9:00 AM ET
Canbiola, Inc. (OTC PINK: CANB) is pleased to announce the hire of Mr. David Posel as the Chief Operations Officer.

"We are excited that Mr. Posel is joining the Canbiola team. Mr. Posel is a pioneer in the CBD industry and his many years of experience in Operations and Manufacturing will allow our company to better manage our growth," said Marco Alfonsi, Canbiola CEO. "David has the perfect background, having participated in the industry since its early stages."

"I am really excited to come aboard and work with Canbiola, a fantastic and robust company. Our goal at Canbiola will be to fo rmulate new products and to continuously improve our product quality. We will be focusing on natural products that symbiotically work with the bio-absorption and bio-delivery systems within the human body and we are poised to deliver the most advanced CBD products across the board," said Mr. Posel.

As the Chief Operations Officer of Canbiola, David will expand the company's product lines across the board, engage market leaders and produce first-to-market products for CBD industry worldwide.

David Posel started his earliest years as a metallurgical engineer at AGCO Metalex, a large precious metals refinery in Washington State. The son of a Ph.D. chemist, Boeing engineer and mathematics major, he quickly went on to the Semiconductor manufacturing industry for nearly a decade as a metallic silicon coatings engineer, leaving to attend ASU West in Arizona. With an engineering and metallurgical chemistry background, David switched gears to Organic agricultural production for an additional eight years. David was farm director and chief environmental scientist for what was once the oldest Organic farm in the state of Colorado before moving into the more advanced world of CBD, hemp production and custom product development. David has spent years earning the respect of CBD market leaders and forming solid business relationships both in the US and abroad. His career began by making the first CBD infused consumer product offered in the US with 99% isolate, 'CrystalPure CBD' which is now sold under the Canbiola brand.

Canbiola will be attending the Integrative Healthcare Symposium Annual Conference on February 22-24, 2018 in New York City. Come join us and learn about the benefits of our products. (Booth # 638)

About Canbiola, Inc.

Canbiola, Inc. is a public company trading under symbol CANB.

Canbiola, Inc. is a US Company emb arking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states. The company has already launched several products found at www.canbiola.com.

The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one so lution for document management, retention and compliance.

Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Canbiola Investor Relations Email: IR@canbiola.com Phone: (516) 595-9544 website: http://www.canbiola.com Follow us on Twitter and Facebook https://resource.globenewswire.com/Resource/Download/f3ca1098-2d37-4eda-82bf-071b21715016?size=1

you just joined ihub and have made 6 negative posts on Canbiola, you have some sort of agenda?

interesting, the products I received where actually real so must be made somewhere

That address would not prevent them from having a manufacturing facility at another location, would it?

http://berryrecorder.com/investors-are-taking-a-closer-look-at-canbiola-inc-otcpkcanb/613118/

Canbiola, Inc. (CANB) Announces the Addition of Dr. Channing Coe to the Medical Advisory Board.
HICKSVILLE, NY / ACCESSWIRE / February 13, 2018 / Canbiola, Inc. (OTC PINK: CANB) in its continuing effort to attract and partner with industry experts in the Global Health and Wellness field, is proud to announced today that Dr. Channing Coe is joining the Medical Advisory Board and has also signed on as a Distributor. Dr. Coe stated, “I am pleased and honored to join the Medical Advisory Board at Canbiola. I am very encouraged with the benefits of Canbiola’s CBD products and the potential for therapy with a wide range of female medical issues. The research and dedication of Canbiola to further our understanding of the medical benefits of CBD are extremely important to my patients’ medical well-being.”
Marco Alfonsi, Canbiola CEO, stated, “We are continuing to execute our plan to strengthen not only our Medical Advisory Board but also our distribution network. With the addition of Dr. Coe, we have added the 6th Doctor to our Medical Advisory Board and believe this last addition will enhance our product development in new areas and further grow sales and geographically expand our client base.”
Dr. Coe joins a medical advisory team that already has the following members:
Dr. Robert A. Kornfeld Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. John P. Salerno Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. Harry Benisatto joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. Smita Ohri joins Canbiola as Medical Advisor and Distributor

About Dr. Channing Coe, MD. / Medical Advisor
Dr. Coe is a practicing Obstetrician and Gynecologist with a special focus on Robotic Minimally Invasive Surgery, his practice also focuses on treating women with chronic pain, endometriosis, and menstrual and menopausal symptoms. Dr. Coe incorporates Eastern and Western medicine as well as nutritional and herbal supplements to help patients realize their true potential.
Certifications and Training:
• Doctor of Medicine 1998 – St Georges University
• Residency – Obstetrics & Gynecology – St. Joseph’s/Columbia/NYU 2002
• Chief Resident Ob/Gyn 2002
• Certified in Minimally Invasive Laparoscopic Surgery
• Active Private Practice since 2002
• Robotic Surgical Proctor since 2009
Member of American College of Obstetrics & Gynecology
Member of Society of Laparoendoscopic Surgeons
Member of American Medical Association
Canbiola will be attending the Integrative Healthcare Symposium Annual Conference on February 22-24, 2018 in New York City. Come join us and learn about the benefits of our products. (Booth # 638)
About Canbiola, Inc.
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states. The company has already launched several products found at www.canbiola.com.
The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.
Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.
CONTACT INFORMATION
Canbiola Investor Relation
Email: IR@canbiola.com
Phone: (516) 595-9544
website: http://www.canbiola.com
Follow us on Twitter and Facebook

Looks like medical team is strengthening:

https://canbiola.com/management-team/

Looks like 3M insider buy

should get sales going in Florida.

On January 24, 2018, Canbiola, Inc. (the “Company”) entered into a Consulting Agreement (the “Agreement”) with Dr. Channing Coe (“Dr. Coe”). Pursuant to the Agreement, Dr. Coe agreed to provide strategic planning and market services to the Company from a medical standpoint.

https://www.sharecare.com/doctor/dr-channing-b-coe

Yeah, probably better if they provided no jobs right?

Cover your shorts ??

It will break over $1,500 today in my opinion - might even get a short squeeze from yesterday's shorters

http://spotlightgrowth.com/index.php/2018/01/30/canbiola-inc-otc-pink-canb-overlooked-unique-cbd-company-high-sales-growth/

Canbiola, Inc. Prepares For Strong 2018, Looking To Continue Impressive Sales Growth - Spotlight Growth

January 31, 2018 07:00 ET | Source: Spotlight Growth
Sacramento, CA, Jan. 31, 2018 (GLOBE NEWSWIRE) -- A new report has been published on Canbiola, Inc. (OTCPINK: CANB). Canbiola is a Hicksville, New York-based company that is engaged within the sale and distribution of premium hemp-based cannabidiol (CBD) consumer products. Products available include: oils, lotions, creams, gels, moisturizers, vapes, chews, isolates, gel caps, concentrates, and more. Canbiola, Inc. stands apart from other CBD producers in that it utilizes state-of-the-art nanotechnology to break down the CBD molecule sizes to 30-60 nanometers, using ultrasonic sound waves. This process allows for high bioavailability of active ingredients.

The report provides an overview of Canbiola, Inc., its CBD operations, financials, industry analysis, and more. The content also covers the outlook of the global hemp-based CBD market.

Brightfield Group: Hemp CBD Market Worth $1 Billion By 2020

Public opinion continues to shift in favor of cannabis legalization and decriminalization. However, not everyone wants to utilize cannabis in order to get “high,” as associated with the tetrahydrocannabinol (THC) compound found in marijuana. CBDs provide the opportunity for consumers to benefit from the medicinal properties of cannabis without becoming intoxicated. As more US states have legalized recreational cannabis, CBDs have seen their popularity surge in recent years.

According to the market research firm, Brightfield Group, the hemp CBD market is forecast to be worth $1 billion by 2020, which represents a compound annual growth rate (CAGR) of 55% between 2017 and 2020. The market research firm sees the growth in CBDs being fueled by the fact that hemp-derived CBDs are legal in all 50 states and the fact that it has remained “under the radar” of the regulatory uncertainty surrounding the emerging cannabis industry.

Canbiola Sees Massive Sales Growth During Fourth Quarter 2017

After successfully transitioning from a software & technology company to the cannabis industry in 2017, Canbiola is prepared for big results in its first full year focused on CBD business. In a press release from early January 2018, Canbiola issued a shareholder update and review of 2017. The company announced that it has effectively built out its Medical Advisory Board with five highly-qualified medical professionals.

The premium CBD company also announced in the press release that it saw explosive product sales growth during the fourth quarter. “We will report our 4th Quarter and full year (2017) results of operations in our 2017 annual report, but can announce today that product sales (unaudited) for the 4th quarter exceeded the combined product sales (unaudited) for the 3 preceding quarters of 2017.”

Canbiola, Inc. (OTC Pink: CANB) established a manufacturing agreement with a third-party manufacturer during the third quarter 2017. The agreement includes a 10-year option to purchase the manufacturing facility from the third party.

The manufacturing agreement will allow the company to directly manufacture its products (at manufacturers’ cost) and white-label other product with no worry of up-front fees. This essentially makes Canbiola self-sufficient and no longer at the mercy of outside manufacturers. Not to mention, this will allow the company to see a major improvement on its operating margins.

As a result of streamlining its supply chain and manufacturing process, Canbiola recently announced that it is passing the savings onto its customers by cutting product prices by nearly 30% across the board.

Overall, Canbiola, Inc. is a unique CBD company that utilizes proprietary technologies to create a product with high bioavailability of the active ingredients. Furthermore, they are one of the few CBD companies that actually tests their products to ensure quality and a balanced product. Canbiola, Inc. utilizes Dragon Analytical Labs for its product testing needs. As Canbiola, Inc. closed out 2017 with massive sales growth, the company stands prepared for strong results in 2018.

For more information on Canbiola, Inc., please visit https://canbiola.com and http://spotlightgrowth.com/index.php/2018/01/30/canbiola-inc-otc-pink-canb-overlooked-unique-cbd-company-high-sales-growth/

SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated five hundred dollars cash for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/



Contact:
Matt Rego
9165257147
mrego@spotlightgrowth.com

aha - didn't catch that
Think I found it: https://appext20.dos.ny.gov/corp_public/CORPSEARCH.ENTITY_INFORMATION?p_token=AAECD0ED525A649F9DD9BB42D1EF99BFE3A27C1BAC74A7E22228D98C2F560D36337CE527DA67F14E67352A2FC0AA8D1D&p_nameid=A272D1514681CB33&p_corpid=D6EF6FF54C0EF8D3&p_captcha=14461&p_captcha_check=AAECD0ED525A649F9DD9BB42D1EF99BFE3A27C1BAC74A7E22228D98C2F560D362C1E451B812C1B48E46F123D4CE3B5DE&p_entity_name=Pure%20Health%20Products&p_name_type=A&p_search_type=BEGINS&p_srch_results_page=0

Might not be NY State.

Thirty-four (34) states have defined industrial hemp as distinct and removed barriers to its production. These states will be able to take immediate advantage of the hemp research and pilot program provision of Section 7606 of the Farm Bill: Alabama, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Indiana, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming and Virginia.

http://www.votehemp.com/us-state-industrial-hemp-legislation.html

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT

Item 1.01 Entry into a Material Definitive Agreement.


On January 24, 2018, the Company entered into a Production Agreement (the “Agreement”) with Pure Health Products, LLC, a New York limited liability company (“PHP”). Unless otherwise terminated or extended pursuant to the terms and conditions of the Agreement, the Agreement shall have a term of ten (10) years. Pursuant to the Agreement, PHP shall manufacture, package, and sell the Company’s proprietary Cannabidiol (“CBD”) infused products (the “Products”) on an exclusive basis. PHP shall not produce or manufacture any product containing any cannabis or hemp derivative for any person or entity other than the Company. The Company shall have the right, at any time, to monitor and review the practices and procedures of PHP in the production and packaging of the Products and to inspect the facility in which PHP performs such services (the “Facility”). The Company controls the ingredients, recipe, manufacturing processes and procedures and quality and taste parameters for all Products produced at the Facility.


The Company shall be responsible for all costs associated with manufacturing of the Products, at PHP’s cost, with no mark-up or margin due to PHP. The Company will separately pay all expenses incurred by PHP for the shipment and delivery of ordered Products, including without limitation freight charges, import duties and insurance premiums, and any federal and state excise taxes, which PHP may pass along to the Company if PHP pays such taxes in compliance with federal laws. The Company shall determine, in its sole discretion, the price at which it resells Products to the Company’s customers.


PHP may also white label / rebrand or relabel the Products pursuant to “white label agreements” entered into between the Company and third party customers.


The Company has granted PHP a non-exclusive, non-transferable, revocable right to use the “Canbiola” trademark (“Canbiola Mark”) solely on the Products ordered by the Company pursuant to the Agreement and associated packaging. PHP has warranted that the Products manufactured and sold by it will be free from defects in material and workmanship, and will substantially conform to the technical specifications provided by the Company in writing. The Company shall be responsible for any warranty it extends, either directly or indirectly, expressly or by operation of law, beyond the warranty expressly granted by PHP. PHP is not responsible for (i) damages caused by the Company’s failure to perform its responsibilities or (ii) damages due to deterioration during extended periods of storage by the Company. PHP shall be responsible for all Product recalls.


Pursuant to the Agreement, the Company agreed to indemnify, defend and hold PHP harmless from and against any damages, claims, suits, actions, causes of action, demands, liabilities, losses, costs and expenses (including without limitation reasonable attorneys' fees and disbursements and court costs) as a result of or arising from any representations or warranties made by the Company to customers or end users which (a) exceed the scope of the representations or warranties made by PHP to the Company; or (b) contradict the documentation and/or information made available to the Company by PHP regarding specifications, performance and intended use of the Products, provided that (i) PHP shall have promptly provided the Company written notice thereof and reasonable cooperation, information and assistance in connection therewith, and (ii) the Company shall have sole control and authority with respect to the defense, settlement or compromise thereof. The Company acknowledges that PHP may perform its services pursuant to the Agreement through subsidiaries and the Company’s indemnification shall apply to all PHP subsidiaries, affiliates and agents providing services to the Company pursuant to this Agreement.

Amazon (AMZN), Berkshire Hathaway (BRK.A) and JPMorgan Chase & Co. (JPM) announced Tuesday a partnership to address health care for their U.S. employees, with the goal of improving employee satisfaction while reducing costs.


The three companies will form an independent company to pursue this objective “free from profit-making incentives and constraints,” according to the companies’ release on the partnership.

The initial focus of the new company will be on technology solutions that will provide U.S. employees and their families with simplified, high-quality and transparent health care at a reasonable cost.

All three of the companies’ leaders weighed in on the partnership, with Berkshire Hathaway chairman and CEO Warren Buffet saying: “The ballooning costs of healthcare act as a hungry tapeworm on the American economy. Our group does not come to this problem with answers. But we also do not accept it as inevitable. Rather, we share the belief that putting our collective resources behind the country’s best talent can, in time, check the rise in health costs while concurrently enhancing patient satisfaction and outcomes.”

“Hard as it might be, reducing healthcare’s burden on the economy while improving outcomes for employees and their families would be worth the effort,” said Amazon founder and CEO Jeff Bezos.

“Our people want transparency, knowledge and control when it comes to managing their healthcare. The three of our companies have extraordinary resources, and our goal is to create solutions that benefit our U.S. employees, their families and, potentially, all Americans,” said Jamie Dimon, chairman and CEO of JPMorgan Chase.

The effort announced today is in its early planning stages, and the companies will provide further details as they are available.

Canbiola, Inc. (CANB) Streamlines Its Supply Chain, Allowing a Nearly 30% Price Reduction Across all Product Lines
HICKSVILLE, NY / ACCESSWIRE / January 29, 2018 / Canbiola, Inc. (OTC PINK: CANB) is announcing that it has signed a contract that allows it to take total control of its supply chain, cutting out the middle-man and third-party manufacturing fees. ''We're now in control of our raw materials procurement and manufacturing process, which is expected to reduce the company's overall operating expenses while maintaining its profit margins. The new deal allows the company to fulfill its mission to improve the quality and costs of our products for our customers,'' says Marco Alfonsi, Canbiola, CEO.

''Our products benefit our clients with a variety of health issues, naturally, but the industry cost is high and reducing our overall production costs allows us to decrease our retail prices to customers and increase our market share. Canbiola is committed to bringing the highest quality products in the most cost-effective way to its customers, something we believe is beneficial to all. Our customers will get more for their hard-earned money and the company should benefit through solid growth in revenues and profit because of these new hypercompetitive prices,'' Mr. Alfonsi concludes.

Canbiola is always striving to make our products available to all who want to lead a lifestyle free of traditional medicine and the intake of prescription drugs. It's our belief that our customers always come first and foremost. New prices are now in effect and our web store can be found at https://canbiola.com/shop-all/.

About Canbiola, Inc.

Canbiola, Inc. is a public company trading under symbol CANB.

Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD industry. The company has already launched several products found at www.canbiola.com. It should be noted that cannabis is currently federally illegal and has been legalized for medical purposes in some form in only a limited number of states; however, the company's CBD is sourced from industrial hemp, which is thought to be permissible under federal law when product contents contain less than 0.03% THC.

The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words ''anticipate,'' ''believe,'' ''estimate,'' ''may,'' ''intend,'' ''expect,'' and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to many risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Contact Information:

Canbiola Investor Relation
Email: IR@canbiola.com
Phone: (516) 595-9544
Website: http://www.canbiola.com
Follow us on Twitter and Facebook

SOURCE: Canbiola, Inc.

News Provided by ACCESSWIRE via QuoteMedia

Let's leave politics off the board please, serves no purpose.

Looks like Feb 1

Add BMIC to the group of MM (ETRF, VNDM, CDEL) that are playing games (manipulating?) with this stock.

Amazon expected to report after close January 31

all we need is for ETRF, VNDM and CDEL to stop playing games - looks like daily shorting and trading in-between themselves.

Great interview: https://vimeo.com/251219187

Got this and CANB - both looking stronger day by day

no idea

what duck?

BusinessWire, GlobeNewswire and PR Newswire News
Canbiola Inc CANB:OTC Pink - Current Information
Grey Cloak (OTCQB: GRCK) Announces Strategic Partnership With Canbiola, Inc
GlobeNewswire
9:01 AM ET
- Grey Cloak Tech Inc., (OTCQB: GRCK) today announced a strategic partnership with Canbiola, Inc. (OTC: CANB) to list their products on the CBD.co marketplace.

"We're pleased to be doing a Joint Venture with CBD.co, for the simple reason CBD.Co does the rigorous vetting of all of the products that reside on their site, that's a creating incredible Marketplace for CBD vendors that qualify," said Marco Alfonsi, CEO of Canbiola Inc. (CANB) in a recent interview with Grey Cloak Tech CEO Patrick Stiles.

"It's important to have our two companies work together to create a marketplace that's ame nable to everybody's thought process moving forward because at the end of the day it's all about sales. If you can't sell a product and can't get the word out there, you get stifled," said Marco Alfonsi.

To kick off the relationship, Grey Cloak's Chief Executive Officer, Patrick Stiles, interviewed Canbiola's CEO, Marco Alfonsi, and Medical Advisory Board Member, Dr. Robert Kornfield, discussing the partnership and the Canbiola products.

These interviews can be found at cbd.co/canbiola

The video interviews are part of CBD.co's brand new initiative, CBD TV, to create video content around CBD and educate consumers on the different brands and products. CBD TV includes interviews, product reviews and education related to hemp and CBD.

Canbiola announced in the last quarter of 2017 they established a manufacturing agreement with a 3rd party manufacturer in the U.S. whereby Canbiola will be able to directly manufacture at manufacturers cost and white-label others' products with no upfront fees due from Canbiola. This step makes Canbiola self-sufficient so that we no longer must rely on outside manufacturers, while greatly improving our operating margins from the reduced costs associated with the new agreement. Having this Strategic Alliance with the manufacturing process allows them to leverages state of the art nanotechnology using ultrasonic sound waves to break down the CBD molecule to the size of 30-60 nanometers. This technology leads to high bioavailability of the active ingredients.

Canbiola also has 5 medical advisors on staff including Dr. John P. Salerno,

Patrick Fratellone M.D. RH (AHG) FIM, Smita Ohri M.D., Dr. Harry Benisatto who advise on research and product development.

"We feel 2018 will be exciting for our two companies working together. Moving forward, I think we can tackle the market together," said Mr. Alfonsi.

CBD.co also started taking Bitcoin and Litecoin cryptocurrencies last week. Opening up the different payments that its customers can use on the site.

Patrick Stiles, Grey Cloak's Chief Executive Officer said, "Canbiola is the exact type of brand we want on the CBD.co marketplace. They are a premier brand with unique proprietary technology. I'm sure our customers will love their products."

About Grey Cloak Tech, Inc.

The Company now has two distinct business lines. The Company is still engaged in the sale of cloud-based software to detect advertising fraud on the internet, and through the acquisition of its wholly-owned subsidiary, Eqova Life Sciences, the Company entered the business of distributing a full spectrum of hemp oil products.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility," and "anticipate." The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Actual results could differ materially from current project

ns or implied results. Investors should read the risk factors set forth in the Compa ny's Annual Report on Form 10-K filed with the SEC on April 17, 2017 and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

For more information, visit http://www.greycloaktech.com. http://www.cbd.co

7022016450 https://resource.globenewswire.com/Resource/Download/582c34b4-1662-404c-8c4f-33d81a2233f2?size=1

News out: https://cbd.co/canbiola/

Not sure, it was 2.2 last year

Earnings Feb 2 I believe, in that case Feb 3 could easily be up $100

Got a good feeling here but also hope the MM stop playing games

Two new targets set, UBS at $1,440 and Stifel Nicolaus at $1,425

primed and ready to move up if only ETRF will stop playing games

If CDEL, ETRF and VNDM would stop their games that sure looks like naked shorting to me then this stock would have a lot of oxygen to ascend!

Newsweek article: WHO claim CBD isn't dangerous!

MEDICAL MARIJUANA'S MAIN INGREDIENT ISN'T DANGEROUS OR ADDICTIVE, WORLD HEALTH ORGANIZATION REPORT SAYS
BY MELINA DELKIC ON 12/14/17 AT 11:03 AM

A top global health agency has declared the main ingredient in medical cannabis nonaddictive and nontoxic, according to a new report.

“In humans, CBD exhibits no effects indicative of any abuse or dependence potential,” wrote the World Health Organization, a U.N. agency that focuses on public health. Researchers spent months looking into cannabidiol, or CBD, the non-psychoactive ingredient in marijuana that’s often used for medical purposes. It often comes in the form of oils, drops or capsules.

The organization’s Expert Committee on Drug Dependence (ECDD) found “no evidence of public health related problems associated with the use of pure CBD.” They also found that, according to several clinical trials, CBD could be good for treating epilepsy and “a number of other medical conditions.”

Although the report came out in November, it drew international attention only on Wednesday, after the WHO published concrete recommendations from the ECDD’s November meeting. In addition to recommending a stricter scheduling for a type of opioid, the committee recommended a new approach to cannabis, responding to increased interest among its member states in researching and legalizing it.

In emails to Newsweek, spokespeople for the WHO clarified that the report very clearly "does not say that WHO recommends the use of cannabidiol." What the WHO recommends "is that cannabidiol should not be scheduled for international control on the basis of current evidence, and that a fuller review will be carried out next year, when other cannabinoids are discussed."

The committee said that CBD did not need to be controlled (or government-regulated) on an international level, and that this should be left up to individual nations. "Saying it should not be scheduled for international control means that it should not be prohibited, at the international level, to produce and supply it for specific purposes, such as medical treatment and research, given that WHO has not so far seen evidence of potential for abuse or harm from cannabidiol," a spokesperson wrote. "As to what is legal or illegal, that comes under national law, so it is up to countries to decide."

The committee will start the expanded review of CBD in May 2018, when it will make more specific recommendations and conclusions.

The legality of CBD has been a source of confusion for years. Even though it’s the non-psychoactive ingredient in marijuana, the Drug Enforcement Administration emphasized in 2016 that it is still illegal and still a Schedule I substance, along with drugs like heroin and LSD. The DEA does not recognize a distinction between CBD and any other kinds of marijuana.

Even though the DEA once eased trials for CBD in late 2015, it released a statement in July saying that CBD was still very much illegal. "Because 'Charlotte's Web'/CBD oil is not an FDA-approved drug...it is a schedule I controlled substance under the [Controlled Substances Act]," the DEA said.

Because marijuana is a Schedule I drug, the DEA rarely approves research on it. And even though many states have legalized it for medical and recreational use, it remains illegal on the federal level.

Proponents in the U.S. have long argued that states and researchers should at least be allowed to look into CBD's benefits and either prove or disprove them.

Even some Republicans, who are typically more hesitant about marijuana legalization, are beginning to agree. Senator Orrin Hatch (R-Utah) introduced a bill to that effect. “We lack the science to support use of medical marijuana products like CBD oils, not because researchers are unwilling to do the work but because of bureaucratic red tape and over-regulation,” Hatch said.

Link: http://www.newsweek.com/medical-marijuana-cbd-not-addictive-toxic-who-says-748069

Market Makers VNDM, ETRF and CDEL playing games again - hopefully regrettable!

Price today will look very cheap shortly imho